Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
Publication
, Journal Article
Zhan, H; Yang, L; Liu, Y; Li, H; Li, X; Wang, H; Cao, J; Kang, S; Guo, X; Dai, E; Li, Y
Published in: J Infect
May 2023
Duke Scholars
Published In
J Infect
DOI
EISSN
1532-2742
Publication Date
May 2023
Volume
86
Issue
5
Start / End Page
e138 / e141
Location
England
Related Subject Headings
- Vaccines, Inactivated
- Tuberculosis
- SARS-CoV-2
- Microbiology
- Immunogenicity, Vaccine
- Immunization, Secondary
- Humans
- COVID-19 Vaccines
- COVID-19
- Antibodies, Viral
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhan, H., Yang, L., Liu, Y., Li, H., Li, X., Wang, H., … Li, Y. (2023). Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis. J Infect, 86(5), e138–e141. https://doi.org/10.1016/j.jinf.2023.01.030
Zhan, Haoting, Li Yang, Yongmei Liu, Haolong Li, Xiaomeng Li, Haibin Wang, Jinfeng Cao, et al. “Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.” J Infect 86, no. 5 (May 2023): e138–41. https://doi.org/10.1016/j.jinf.2023.01.030.
Zhan H, Yang L, Liu Y, Li H, Li X, Wang H, et al. Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis. J Infect. 2023 May;86(5):e138–41.
Zhan, Haoting, et al. “Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.” J Infect, vol. 86, no. 5, May 2023, pp. e138–41. Pubmed, doi:10.1016/j.jinf.2023.01.030.
Zhan H, Yang L, Liu Y, Li H, Li X, Wang H, Cao J, Kang S, Guo X, Dai E, Li Y. Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis. J Infect. 2023 May;86(5):e138–e141.
Published In
J Infect
DOI
EISSN
1532-2742
Publication Date
May 2023
Volume
86
Issue
5
Start / End Page
e138 / e141
Location
England
Related Subject Headings
- Vaccines, Inactivated
- Tuberculosis
- SARS-CoV-2
- Microbiology
- Immunogenicity, Vaccine
- Immunization, Secondary
- Humans
- COVID-19 Vaccines
- COVID-19
- Antibodies, Viral